Tag Archives: Ram Selvaraju

H.C. Wainwright Thinks Aquestive Therapeutics Inc’s Stock is Going to Recover

Aquestive Therapeutics Inc (AQST – Research Report) received a Buy rating and a $10 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed on Thursday at $6.29, close to its 52-week low of $5.60. Selvaraju said:

AzurRx BioPharma Inc (AZRX) Received its Third Buy in a Row

After Oppenheimer and Maxim Group gave AzurRx BioPharma Inc (NASDAQ: AZRX) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ram Selvaraju reiterated a Buy rating on AzurRx BioPharma Inc today and set

H.C. Wainwright Sticks to Its Buy Rating for Acer Therapeutics Inc (ACER)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Acer Therapeutics Inc (ACER – Research Report) today and set a price target of $55. The company’s shares closed yesterday at $25.61. Selvaraju observed: “Valuation methodology and risks. We value

Ironwood Pharma (IRWD) Receives a Hold from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Ironwood Pharma (IRWD – Research Report), with a price target of $14. The company’s shares closed on Friday at $11.48. Selvaraju noted: “We utilize a

Oramed Pharmaceuticals (ORMP) Receives a Buy from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oramed Pharmaceuticals (ORMP – Research Report), with a price target of $25. The company’s shares closed on Friday at $4.15. Selvaraju observed: “Valuation methodology, risks

CytomX Therapeutics Inc (CTMX) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on CytomX Therapeutics Inc (CTMX – Research Report) today and set a price target of $34. The company’s shares opened today at $10.80, close to its 52-week low of $9.38. Selvaraju